Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chip array data for human PDAC Suit2-007 in primary (pancreas) secondary organs (liver and lungs) of a PDAC rat model

ABSTRACT: Chip array data for human PDAC Suit2-007 in primary (pancreas) secondary organs (liver and lungs) of a PDAC rat model

PROVIDER: PRJNA638930 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Chip array data for human PDAC Suit2-007 in primary (pancreas) secondary organs (liver and lungs) of a PDAC rat model

Project description:We report the gene expression profile of human PDAC Suit2-007 in primary (pancreas) secondary organs (liver and lungs) of a PDAC rat model

2020-09-01 | GSE152305 | GEO

Chip array data for Suit2-007 cells treated by riproximin (Rpx)

Project description:We report the effect of Rpx on human PDAC Suit2-007 cells after 48h time point

2020-09-01 | GSE152304 | GEO

Chip array data for Suit2-007 cells treated by riproximin (Rpx)

Project description:Chip array data for Suit2-007 cells treated by riproximin (Rpx)

| PRJNA638931 | ENA

Gene expression profiles in S2-007, S2-020 and S2-028 pancreatic ductal adenocarcinoma cell lines

Project description:To investigate the subcellular localization of maspin in pancreatic ductal adenocarcinoma (PDAC) and its functional relevance, gene expression profiles were analyzed in S2-007 (expressing nuclear and cytoplasic maspin), S2-028 (expressing cytoplasmic-only maspin), and S2-020 (expressing weakly maspin) cells. The data provides insight into the differential function of maspin in PDAC depending on its subcellular localization.

2025-12-24 | GSE314358 | GEO

Expression data from advanced stage of murine pancreatic ductal adenocarcinoma (PDAC) and control pancreas

Project description:We used microarrays to detail the global gene expression signature of PDAC and to identify distinct up- and down-regulated transcripts in these tumors compared to control pancreas. We also established from this dataset the metabolic signature of PDAC in order to define new metabolic therapeutic target for pancreatic cancer. PDAC were removed at an advanced stage of tumorigenesis in 7 to 10-weeks old mice with Mixed genetic background : B6CBAF1 x C57BL/6 x 129/Sv x FVB/n. Apparent signs used to determined the time of sacrifice : weight loss, lower activity and dull coat.

2014-09-16 | E-GEOD-61412 | biostudies-arrayexpress

Expression data from pre-cancerous pancreatic tissue from a murine model of pancreatic ductal adenocarcinoma (PDAC) and control pancreas

Project description:We used microarrays to detail the global gene expression signature of PDAC and to identify distinct up- and down-regulated transcripts in pre-cancerous pancreatic tissue compared to control pancreas. We also established from this dataset the metabolic signature of pre-cancerous pancreas to define new metabolic therapeutic targets for PDAC.

2025-11-13 | GSE284155 | GEO

Expression data from advanced stage of murine pancreatic ductal adenocarcinoma (PDAC) and control pancreas

2014-09-16 | GSE61412 | GEO

Expression data from intermediate stage of murine pancreatic ductal adenocarcinoma (PDAC) and control pancreas

2022-02-17 | GSE127891 | GEO

Profiling of Kallikrein Proteases and Global Proteome Biology of PDAC, Chronic Pancreatitis and Normal Pancreas

Project description:Cell conditioned medium from human pancreatic cancer cell lines MiaPaCa-2, AsPC-1, primary pancreatic cell lines as well as human FFPE tissue samples from pancreatic ductal adenocarcinoma (PDAC), chronic pancreatitis (CP), ampullary cancer, non-malignant adjacent pancreas and normal pancreas were analyzed via targeted (SRM, PRM) and/or explorative (DIA) mass spectrometry.

| MSV000090255 | MassIVE

ChIP-seq analysis of RARB enrichment in SUIT2 pancreatic cancer cells

Project description:The aim of the experiment was to identify genome wide binding sites for retinoic acid receptor beta (RARB) in RARB agonist treated human metastatic pancreatic ductal adenocarcinoma cells (SUIT2). Datasets are prsented for the ChIP-seq analysis for SUIT2 cells after 72 h treatment with either DMSO (vehicle control), 1 µM RAR-β agonist (CD 2314, Tocirs 3824), or 1 µM RAR-β antagonist (LE 135, Tocris 2021).

2023-05-01 | E-MTAB-12792 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data